Skip to main content

Table 3 Clinical trials of PARPi and cell cycle inhibitor administration in cancers

From: The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment

NCT number

Intervention

Target

Disease setting

Phase

Trial status

Result

04,149,145

M4344 + Niraparib

ATRi + PARPi

PARPi-resistant recurrent ovarian cancer

I

Not yet recruiting

/

04,655,183

M4344 + Niraparib

ATRi + PARPi

Advanced solid tumors

Breast cancer with DDR mutations

I/II

Withdrawn

/

04,170,153

M1774 + Niraparib

ATRi + PARPi

Metastatic or locally advanced Unresectable solid tumors

I

Recruiting

/

02,723,864

VX-970 + Veliparib

 + Cisplatin

ATRi + PARPi

 + Platinum

Refractory solid tumors

I

Completed

0/3;0/3;2/6;0/7;0/3;3/25;0/6 ORRs in each arms

1/3;2/3;5/6;4/7;3/3;10/25;3/6 DCRs in each arms

04,267,939

BAY1895344 + Niraparib

ATRi + PARPi

Advanced solid tumors (excluding prostate cancer)

Ovarian cancer

Ib

Recruiting

/

02,264,678

AZD6738 + Olaparib

ATRi + PARPi

Advanced solid malignance—H&N SCC, ATM Pro/Def NSCLC, gastric, breast and ovarian cancer

I/II

Recruiting

/

03,462,342

AZD6738 + Olaparib

ATRi + PARPi

Recurrent ovarian cancer (platinum-sensitive or platinum-resistant cohort)

II

Recruiting

/

04,065,269

AZD6738 + Olaparib

ATRi + PARPi

Relapsed ovarian (fallopian tube/primary peritoneal) and endometrial (uterus) clear cell carcinomas with/without loss of ARID1A expression

Other rare relapsed gynecological cancers (endometrioid ovarian carcinoma, endometrioid endometrial carcinoma, cervical adenocarcinoma, cervical squamous, ovarian carcinosarcoma and endometrial carcinosarcoma) irrespective of ARID1A status

II

Recruiting

/

03,682,289

AZD6738 + Olaparib

ATRi + PARPi

Clear cell/metastatic/stage III/IV renal cell carcinoma

Locally advanced/metastatic/stage III/IV pancreatic cancer

Locally advanced/metastatic malignant solid neoplasm

Metastatic urothelial carcinoma

II

Recruiting

/

04,239,014

AZD6738 + Olaparib

ATRi + PARPi

Ovarian cancer

II

Withdrawn

/

04,090,567

AZD6738 + Olaparib

ATRi + PARPi

Advanced or metastatic breast cancer with germline BRCA1/2 mutations

II

Recruiting

/

02,937,818

AZD6738 + Olaparib

ATRi + PARPi

Platinum refractory extensive-stage small-cell lung carcinoma

II

Active, not recruiting

/

03,787,680

AZD6738 + Olaparib

ATRi + PARPi

Metastatic castration-resistant prostate cancer (mCRPC) with DNA repair proficiency (DRPro)

mCRPC with DNA repair deficiency (DRDef)

II

Active, not recruiting

/

03,428,607

AZD6738 + Olaparib

ATRi + PARPi

Relapsed small-cell lung cancer (SCLC)

II

Completed

/

03,330,847

AZD6738 + Olaparib

AZD1775 + Olaparib

ATRi + PARPi

WEE1i + PARPi

Metastatic triple-negative breast cancer(TNBC) with BRC1/2 mutations

Metastatic TNBC with other HRR gene mutations other than BRCA1/2

Metastatic TNBC without any mutation of HRR genes

II

Active, not recruiting

/

02,576,444

AZD6738 + Olaparib

AZD1775 + Olaparib

ATRi + PARPi

WEE1i + PARPi

Advanced solid tumors with mutations in homologous—DNA repair (HDR) genes or mutations such as ATM, CHK2, MRN (MRE11/NBS1/RAD50), CDKN2A/B and APOBEC

Advanced solid tumors with mutations of TP53 or KRAS gene

II

Active, Not Recruiting

/

03,057,145

Prexasertib + Olaparib

CHK1i + PARPi

Advanced solid tumors

I

Completed

/

02,511,795

AZD1775 + Olaparib

WEE1i + PARPi

Refractory solid tumors

Relapsed small-cell lung cancer (SCLC)

Ib

Completed

11.1% ORR in the total polulation;

55.7% DCR in the total population

03,579,316

AZD1775 + Olaparib

WEE1i + PARPi

PARPi-resistant recurrent ovarian (fallopian tube/primary peritoneal) cancers

II

Recruiting

/